Treatment-free remission in Chronic Myeloid Leukemia harboring atypical BCR-ABL1 transcripts.

Discontinuation of tyrosine kinase inhibitors (TKI) is the main goal today in the field of Philadelphia positive chronic myeloid leukemia (Ph + CML) and the criteria to attempt the interruption of therapy are well defined and rely on the possibility to regularly monitor the BCR-ABL1 transcript. Pati...

Full description

Saved in:
Bibliographic Details
Main Authors: Matteo Dragani, Jessica Petiti, Giovanna Rege-Cambrin, Enrico Gottardi, Filomena Daraio, Giovanni Caocci, Chiara Aguzzi, Elena Crisà, Giacomo Andreani, Francesca Caciolli, Carmen Fava
Format: Article
Language:English
Published: PAGEPress Publications 2020-08-01
Series:Mediterranean Journal of Hematology and Infectious Diseases
Online Access:https://www.mjhid.org/index.php/mjhid/article/view/4306
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850215580019195904
author Matteo Dragani
Jessica Petiti
Giovanna Rege-Cambrin
Enrico Gottardi
Filomena Daraio
Giovanni Caocci
Chiara Aguzzi
Elena Crisà
Giacomo Andreani
Francesca Caciolli
Carmen Fava
author_facet Matteo Dragani
Jessica Petiti
Giovanna Rege-Cambrin
Enrico Gottardi
Filomena Daraio
Giovanni Caocci
Chiara Aguzzi
Elena Crisà
Giacomo Andreani
Francesca Caciolli
Carmen Fava
author_sort Matteo Dragani
collection DOAJ
description Discontinuation of tyrosine kinase inhibitors (TKI) is the main goal today in the field of Philadelphia positive chronic myeloid leukemia (Ph + CML) and the criteria to attempt the interruption of therapy are well defined and rely on the possibility to regularly monitor the BCR-ABL1 transcript. Patients harboring atypical transcripts are automatically excluded from protocols due to the absence of a standardized method of quantification of their minimal residual disease (MRD). We report here the outcome of 6 patients with atypical transcripts with a long follow up whose MRD was followed in three cases with digital PCR during their treatment free remission (TFR).
format Article
id doaj-art-61bfd387faee476c97d0c65d9db95968
institution OA Journals
issn 2035-3006
language English
publishDate 2020-08-01
publisher PAGEPress Publications
record_format Article
series Mediterranean Journal of Hematology and Infectious Diseases
spelling doaj-art-61bfd387faee476c97d0c65d9db959682025-08-20T02:08:35ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062020-08-0112110.4084/mjhid.2020.066Treatment-free remission in Chronic Myeloid Leukemia harboring atypical BCR-ABL1 transcripts.Matteo Dragani0Jessica Petiti1Giovanna Rege-Cambrin2Enrico Gottardi3Filomena Daraio4Giovanni Caocci5Chiara Aguzzi6Elena Crisà7Giacomo Andreani8Francesca Caciolli9Carmen Fava10{'en_US': 'Department of Clinical and Biological Sciences, University of Turin, Orbassano'}Department of Clinical and Biological Sciences, University of Turin, OrbassanoDepartment of Clinical and Biological Sciences, University of Turin, OrbassanoDepartment of Clinical and Biological Sciences, University of Turin, OrbassanoDepartment of Clinical and Biological Sciences, University of Turin, OrbassanoDepartment of Hematology, University of Cagliari, CagliariDepartment of Biotechnologies and Hematology, University of Turin, TurinDepartment of Hematology, University of Oriental Piedmont, NovaraDepartment of Clinical and Biological Sciences, University of Turin, OrbassanoDepartment of Clinical and Biological Sciences, University of Turin, OrbassanoDepartment of Clinical and Biological Sciences, University of Turin, OrbassanoDiscontinuation of tyrosine kinase inhibitors (TKI) is the main goal today in the field of Philadelphia positive chronic myeloid leukemia (Ph + CML) and the criteria to attempt the interruption of therapy are well defined and rely on the possibility to regularly monitor the BCR-ABL1 transcript. Patients harboring atypical transcripts are automatically excluded from protocols due to the absence of a standardized method of quantification of their minimal residual disease (MRD). We report here the outcome of 6 patients with atypical transcripts with a long follow up whose MRD was followed in three cases with digital PCR during their treatment free remission (TFR).https://www.mjhid.org/index.php/mjhid/article/view/4306
spellingShingle Matteo Dragani
Jessica Petiti
Giovanna Rege-Cambrin
Enrico Gottardi
Filomena Daraio
Giovanni Caocci
Chiara Aguzzi
Elena Crisà
Giacomo Andreani
Francesca Caciolli
Carmen Fava
Treatment-free remission in Chronic Myeloid Leukemia harboring atypical BCR-ABL1 transcripts.
Mediterranean Journal of Hematology and Infectious Diseases
title Treatment-free remission in Chronic Myeloid Leukemia harboring atypical BCR-ABL1 transcripts.
title_full Treatment-free remission in Chronic Myeloid Leukemia harboring atypical BCR-ABL1 transcripts.
title_fullStr Treatment-free remission in Chronic Myeloid Leukemia harboring atypical BCR-ABL1 transcripts.
title_full_unstemmed Treatment-free remission in Chronic Myeloid Leukemia harboring atypical BCR-ABL1 transcripts.
title_short Treatment-free remission in Chronic Myeloid Leukemia harboring atypical BCR-ABL1 transcripts.
title_sort treatment free remission in chronic myeloid leukemia harboring atypical bcr abl1 transcripts
url https://www.mjhid.org/index.php/mjhid/article/view/4306
work_keys_str_mv AT matteodragani treatmentfreeremissioninchronicmyeloidleukemiaharboringatypicalbcrabl1transcripts
AT jessicapetiti treatmentfreeremissioninchronicmyeloidleukemiaharboringatypicalbcrabl1transcripts
AT giovannaregecambrin treatmentfreeremissioninchronicmyeloidleukemiaharboringatypicalbcrabl1transcripts
AT enricogottardi treatmentfreeremissioninchronicmyeloidleukemiaharboringatypicalbcrabl1transcripts
AT filomenadaraio treatmentfreeremissioninchronicmyeloidleukemiaharboringatypicalbcrabl1transcripts
AT giovannicaocci treatmentfreeremissioninchronicmyeloidleukemiaharboringatypicalbcrabl1transcripts
AT chiaraaguzzi treatmentfreeremissioninchronicmyeloidleukemiaharboringatypicalbcrabl1transcripts
AT elenacrisa treatmentfreeremissioninchronicmyeloidleukemiaharboringatypicalbcrabl1transcripts
AT giacomoandreani treatmentfreeremissioninchronicmyeloidleukemiaharboringatypicalbcrabl1transcripts
AT francescacaciolli treatmentfreeremissioninchronicmyeloidleukemiaharboringatypicalbcrabl1transcripts
AT carmenfava treatmentfreeremissioninchronicmyeloidleukemiaharboringatypicalbcrabl1transcripts